The Jackson Laboratory Cancer Center (JAXCC) has undergone a major change in leadership with the recruitment of Edison Liu, MD in 2012 to serve as Director (4.8 months calendar effort). Robert Braun, PhD, serves as Deputy Director (2.4 calendar months). Dr. Liu, who is the President and CEO of JAX, was appointed by and reports to the JAX Board of Trustees. He sets the scientific direction and makes all appointments to the JAXCC. He has final authority on all budget decisions, and is responsible for the allocation of all central discretionary and philanthropic funds, space, and equipment for JAX and the JAXCC. Dr. Liu is a physician and researcher whose work on functional genomics of human cancers, particularly breast cancer spans the fields of molecular oncogenesis, epidemiology, genomics, and genetics. He has substantial leadership experience, most recently serving as Executive Director of the Genome Institute of Singapore, which he developed from its inception to an internationally recognized genome center. Dr. Braun, who is the Vice President for Research of JAX, reports to Dr. Liu and works closely with him to foster and implement strategic initiatives and appoint, develop and promote JAXCC members. He has primary responsibility for coordinating research across the 3 JAXCC campuses. Dr. Braun is an expert in male reproduction with a focus on RNA biology, adult stem cells and androgen action. Expansion of the Senior Leadership team was an immediate priority culminating in the appointment of additional senior leaders from the three JAXCC campuses to a Scientific Executive Committee (SEC) with Drs. Liu and Braun to guide the ongoing growth ofthe JAXCC, These include: Carol Bult, PhD, Chengkai Dai, MD, PhD, Neal Goodwin, PhD, Frank McKeon, PhD, Kevin Mills, PhD and Yijun Ruan, PhD. Drs, Bult, Dai and McKeon dedicate 1.2 calendar months to their roles as co-Program Leaders and serve the SEC in that capacity. Dr. Mills serves as Associate Director, Regional Translational Partnerships (1.2 calendar months), and leads the development of collaborative research with New England clinical centers. Dr. Goodwin, Senior Fellow, devotes 0.3 calendar months to integrating the PDX resource with the JAXCC research goals. Dr. Ruan (0.3 months effort) directs the genome technologies development initiative. The SEC meets monthly to plan large collaborative cancer research projects;coordinate and engage the JAXCC membership in the major technology and model development initiatives of the JAXCC;and direct the pilot project program in order to align research development with the strategic goals of the JAXCC. Strengthening translational outreach is a major goal. The senior leadership has formed collaborative relationships with regional cancer care centers in Maine and Connecticut, and has developed relationships with members of SWOG, culminating in membership as a Translational Medicine Member in 2013.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA034196-29
Application #
8699296
Study Section
Subcommittee G - Education (NCI)
Project Start
1997-08-01
Project End
2019-06-30
Budget Start
2014-07-01
Budget End
2015-06-30
Support Year
29
Fiscal Year
2014
Total Cost
$103,389
Indirect Cost
$44,310
Name
Jackson Laboratory
Department
Type
DUNS #
042140483
City
Bar Harbor
State
ME
Country
United States
Zip Code
04609
Gong, Liang; Wong, Chee-Hong; Cheng, Wei-Chung et al. (2018) Picky comprehensively detects high-resolution structural variants in nanopore long reads. Nat Methods 15:455-460
Noorbakhsh, Javad; Kim, Hyunsoo; Namburi, Sandeep et al. (2018) Distribution-based measures of tumor heterogeneity are sensitive to mutation calling and lack strong clinical predictive power. Sci Rep 8:11445
Gatti, D M; Weber, S N; Goodwin, N C et al. (2018) Genetic background influences susceptibility to chemotherapy-induced hematotoxicity. Pharmacogenomics J 18:319-330
deCarvalho, Ana C; Kim, Hoon; Poisson, Laila M et al. (2018) Discordant inheritance of chromosomal and extrachromosomal DNA elements contributes to dynamic disease evolution in glioblastoma. Nat Genet 50:708-717
Mistri, Tapan Kumar; Arindrarto, Wibowo; Ng, Wei Ping et al. (2018) Dynamic changes in Sox2 spatio-temporal expression promote the second cell fate decision through Fgf4/Fgfr2 signaling in preimplantation mouse embryos. Biochem J 475:1075-1089
Leidy-Davis, Tiffany; Cheng, Kai; Goodwin, Leslie O et al. (2018) Viable Mice with Extensive Gene Humanization (25-kbp) Created Using Embryonic Stem Cell/Blastocyst and CRISPR/Zygote Injection Approaches. Sci Rep 8:15028
Raghupathy, Narayanan; Choi, Kwangbom; Vincent, Matthew J et al. (2018) Hierarchical analysis of RNA-seq reads improves the accuracy of allele-specific expression. Bioinformatics 34:2177-2184
Presa, Maximiliano; Racine, Jeremy J; Dwyer, Jennifer R et al. (2018) A Hypermorphic Nfkbid Allele Contributes to Impaired Thymic Deletion of Autoreactive Diabetogenic CD8+ T Cells in NOD Mice. J Immunol 201:1907-1917
Pullagura, Sri Ramulu N; Buaas, Bill; Gray, Nichelle et al. (2018) Functional Redundancy of DICER Cofactors TARBP2 and PRKRA During Murine Embryogenesis Does Not Involve miRNA Biogenesis. Genetics 208:1513-1522
Cho, Sung-Yup; Sung, Chang Ohk; Chae, Jeesoo et al. (2018) Alterations in the Rho pathway contribute to Epstein-Barr virus-induced lymphomagenesis in immunosuppressed environments. Blood 131:1931-1941

Showing the most recent 10 out of 1156 publications